BioSpace9d
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...
Fierce Biotech10d
Immunovant won't seek approval for autoimmune drug despite phase 3 win
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
STAT10d
Immunovant and Roivant report success in autoimmune drug’s Phase 3 trial
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
GlobalData on MSN9d
Immunovant will not seek approval for MG therapy, despite hitting endpoints
The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
Zacks Investment Research on MSN8d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
manilatimes10d
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG ... were observed to be consistent with prior batoclimab studies. Immunovant ...
Immunovant's muscle drug data underwhelms, shares gain on new drug promise
Immunovant's experimental drug to treat a type of chronic muscle weakness improved patients' ability to perform daily tasks, but fell short of the effectiveness set by already approved treatments. The ...
The Pharma Letter9d
Positive batoclimab data from Immunovant, but doubts raised on further development
Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
Morningstar10d
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily ... Path Forward in MG and CIDP Immunovant plans to initiate potentially ...